# LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

> **NCT04577807** · PHASE2 · COMPLETED · sponsor: **Istari Oncology, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Lerapolturev
- **BIOLOGICAL:** Anti-PD-1 Checkpoint Inhibitor

## Key facts

- **NCT ID:** NCT04577807
- **Lead sponsor:** Istari Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-17
- **Primary completion:** 2024-11-15
- **Final completion:** 2024-11-15
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04577807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04577807, "LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04577807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*